Writing $ABSI +44% 🚀 AI Biotech Breaking Out! 🔹 Clinical-stage biotech using generative AI to design next-generation antibody therapeutics 🤖🧬 🔹 Positive in

Writing $ABSI +44% 🚀 AI Biotech Breaking Out! 🔹 Clinical-stage biotech using generative AI to design next-generation antibody therapeutics 🤖🧬 🔹 Positive interim Phase 1 data from the HEADLINE trial for ABS-201 showed favorable safety and tolerability 💥 🔹 Multiple catalysts ahead with proof-of…